Early evaluation of tumor response using contrast-enhanced ultrasonography for hepatocellular carcinoma treated with Solafenib

Early evaluation of tumor response using contrast-enhanced ultrasonography for hepatocellular carcinoma treated with Solafenib - Solafenib efficacy by E-US

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000004599

Enrollment

Registered

2010-11-24

Start date

2010-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: unresectable or incurable HCC

Exclusion criteria

Exclusion criteria: 1. T-Bil >3.0g/dl, PT 50%> 2.woman before menopause 3. woman during pregnancy or breast-feeding, who has plan for pregnancy 4. patient who has massive fluid collection 5. patient whom the doctor think as inappropriate

Design outcomes

Primary

Measure	Time frame
Tumor perfusion ( enhanced ultrasonography, enhanced CT, enhanced MRI)	—

Secondary

Measure	Time frame
Tumor markaer, histological change, liver function, cahnge in tumor size	—

Countries

Japan

Contacts

Public ContactHiroyuki Fukuda

Yokohama City University Medical Center Gastroenterological Center

fukuhiro@yokohama-cu.ac.jp045-261-5656

Outcome results